acute myeloid leukaemia
Experimental Novartis leukaemia and mastocytosis drug gets FDA Priority Review
November 14, 2016Research and Development, Sales and Marketing FDA, Novartis, acute myeloid leukaemia
The US FDA has granted Priority Review status to Novartis’ experimental drug PKC412 (midostaurin) as a treatment for advanced systemic …
Celgene and Agios to file FDA application for “first-in-class” cancer drug
September 8, 2016Research and Development, Sales and Marketing Celgene, FDA, NDA, acute myeloid leukaemia, agios
According to an SEC 8-K filing by Agios, the company and its partner Celgene intend to file a new drug …
Celator receives FDA breakthrough therapy designation for leukaemia drug
May 20, 2016Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator
A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …
Novartis drug PKC412 gets Breakthrough designation for AML
February 19, 2016Medical Communications, Research and Development FDA, Novartis, acute myeloid leukaemia
Novartis’ PKC412 (midostaurin) has become the latest in a sequence of FDA Breakthrough Therapy designations awarded this week- bagging the …
Celgene’s Vidaza earns wider approval
November 2, 2015Sales and Marketing Celgene, European Commission, Vidaza, acute myeloid leukaemia, azacitidine, leukaemia
Swiss firm Celgene has been given approval by the European Commission to extend its marketing authorisation for the cancer treatment …
Trial failures threaten UK biotech
February 18, 2011Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech
A number of late stage failures from British biotech firms have left a looming question mark over the future of …
Latest content
Five Facts about cardiovascular disease
